Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bayer looking for a "mid-size M&A transaction" in oncology

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jun 14, 2023 9:32am

198 Views

Post# 35495641

RE:RE:RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

What I'm getting at, and it concerns me greatly, is how do we arrive at a $200+ a share buyout for a $2.75 a share biotech? Of course, keeping in mind that no one wants to spend many more months or years while MC tries to create value. I know Onc should be worth a truck load, but how would, say Roche, expect shareholders to sign off on deal worth $200 a share for what we currently trade at.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand